Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;115:204-212
Published online before print December 26, 2006, doi: 10.1161/CIRCULATIONAHA.106.629261
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
115/2/204    most recent
CIRCULATIONAHA.106.629261v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lindenfeld, J.
Right arrow Articles by Bristow, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lindenfeld, J.
Right arrow Articles by Bristow, M.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Heart Failure
*Pacemakers and Implantable Defibrillators
Related Collections
Right arrow Congestive
Right arrow Ablation/ICD/surgery
Right arrow Pacemaker

(Circulation. 2007;115:204-212.)
© 2007 American Heart Association, Inc.


Heart Failure

Effects of Cardiac Resynchronization Therapy With or Without a Defibrillator on Survival and Hospitalizations in Patients With New York Heart Association Class IV Heart Failure

JoAnn Lindenfeld, MD; Arthur M. Feldman, MD, PhD; Leslie Saxon, MD; John Boehmer, MD; Peter Carson, MD; Jalal K. Ghali, MD; Inder Anand, MD; Steve Singh, MD; Jonathan S. Steinberg, MD; Brian Jaski, MD; Teresa DeMarco, MD; David Mann, MD; Patrick Yong, MSEE; Elizabeth Galle, MS; Fred Ecklund, MA; Michael Bristow, MD, PhD

From the Department of Medicine, University of Colorado Health Sciences Center (J.L., M.R.B.), and Women’s Health Research Center (J.L.), Denver, Colo; Thomas Jefferson Medical College (A.M.F.), Philadelphia, Pa; University of Southern California (Keck School of Medicine) (L.A.S.), Los Angeles; Milton Hershey Medical Center, Penn State School of Medicine (J.B.), Hershey, Pa; Washington DC Veterans Administration (S.S., P.C.), Washington, DC; Wayne State School of Medicine (J.K.G.), Detroit, Mich; Minneapolis Veterans Administration (I.A.), Minneapolis, Minn; San Diego Cardiac Center (B.J.), San Diego, Calif; University of California (T.M.), San Francisco; Cardiovascular Associates and St Mary and Elizabeth Hospital (D.M.), Louisville, Ky; and Boston Scientific (P.Y., E.G., F.E.), St. Paul, Minn.

Correspondence to Dr JoAnn Lindenfeld, Division of Cardiology, University of Colorado Health Sciences Center, 4200 E. Ninth Ave, B-130, Denver, CO 80262. E-mail joann.lindenfeld{at}uchsc.edu

Received April 7, 2006; accepted October 11, 2006.

Background— Cardiac resynchronization therapy (CRT) alone or combined with an implantable defibrillator (CRT-D) has been shown to improve exercise capacity and quality of life and to reduce heart failure (HF) hospitalizations and mortality in patients with New York Heart Association (NYHA) class III and IV HF. There is concern that the device procedure may destabilize these very ill class IV patients. We sought to examine the outcomes of NYHA class IV patients enrolled in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial to assess the potential benefits of CRT and CRT-D.

Methods and Results— The COMPANION trial randomized 1520 patients with NYHA class III and IV HF to optimal medical therapy, CRT, or CRT-D. In the class IV patients (n=217), the primary end point of time to death or hospitalization for any cause was significantly improved by both CRT (hazard ratio [HR], 0.64; 95% CI, 0.43 to 0.94; P=0.02) and CRT-D (HR, 0.62; 95% CI, 0.42 to 0.90; P=0.01). Time to all-cause death and HF hospitalization was also significantly improved in both CRT (HR, 0.57; 95% CI, 0.37 to 0.87; P=0.01) and CRT-D (HR, 0.49; 95% CI, 0.32 to 0.75; P=0.001) Time to all-cause death trended to an improvement in both CRT (HR, 0.67; 95% CI, 0.41 to 1.10; P=0.11) and CRT-D (HR, 0.63; 95% CI, 0.39 to 1.03; P=0.06). Time to sudden death appeared to be significantly reduced in the CRT-D group (HR, 0.27; 95% CI, 0.08 to 0.90; P=0.03). There was a nonsignificant reduction in time to HF deaths for both CRT (HR, 0.68; 95% CI, 0.34 to 1.37; P=0.28) and CRT-D (HR, 0.79; 95% CI, 0.41 to 1.52; P=0.48).

Conclusions— CRT and CRT-D significantly improve time to all-cause mortality and hospitalizations in NYHA class IV patients, with a trend for improved mortality. These devices should be considered in ambulatory NYHA class IV HF patients similar to those enrolled in COMPANION.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
EuropaceHome page
L. Ding, W. Hua, H. Niu, K. Chen, and S. Zhang
Primary prevention of sudden cardiac death using implantable cardioverter defibrillators
Europace, June 16, 2008; (2008) eun150v1.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. M. Scheinman and E. Keung
The year in review of clinical cardiac electrophysiology.
J. Am. Coll. Cardiol., May 27, 2008; 51(21): 2075 - 2081.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
J. Am. Coll. Cardiol., May 27, 2008; 51(21): e1 - e62.
[Full Text] [PDF]


Home page
CirculationHome page
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
Circulation, May 27, 2008; 117(21): e350 - e408.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
W.H. W. Tang and G. S. Francis
The Year in Heart Failure
J. Am. Coll. Cardiol., December 11, 2007; 50(24): 2344 - 2351.
[Full Text] [PDF]


Home page
Eur Heart J SupplHome page
C. Leclercq, G. B. Bleeker, C. Linde, E. Donal, J. J. Bax, M. J. Schalij, and C. Daubert
Cardiac resynchronization therapy: clinical results and evolution of candidate selection
Eur. Heart J. Suppl., December 1, 2007; 9(suppl_I): I94 - I106.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
C Leclercq
New guidelines for cardiac resynchronisation therapy: simplicity or complexity for the doctor?
Heart, September 1, 2007; 93(9): 1017 - 1019.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W.H. W. Tang and G. S. Francis
Cardiac Resynchronization Therapy in New York Heart Association Class IV Heart Failure: It Is All About Selection
Circulation, January 16, 2007; 115(2): 161 - 162.
[Full Text] [PDF]